Scilex Holding Company SCLX 深 沪
交易中 03-27 10:29:38 美东时间
6.527
-0.053
-0.81%
华盛通- 最 高9.77
- 今 开6.75
- 成交量 4069股
- 最 低 6.45
- 昨 收 6.58
- 总市值 0
- 52周最高 34.27
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.175
- 委 比 0.00%
- 总股本 --
- 历史最高 34.27
- 量 比 0.79
- 振 幅 50.46%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Datavault AI Lifts Outlook On Strong Licensing And Tokenization Growth
Datavault AI Inc. (NASDAQ: DVLT) raises 2025 revenue outlook to $38-$40 million, reaffirms $200 million target for 2026.
02-17 21:20
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board
Scilex Holding Company announced the deferral of its previously announced dividend record date to a later date, with the ability to change or revoke the dividend. The company focuses on non-opioid pain management products and has several commercial products and pipeline candidates targeting acute and chronic pain, neurodegenerative, and cardiometabolic diseases.
2025-06-23 20:50
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Denali Capital Acquisition Corp. deposited $874.78 into its trust account to extend its business combination deadline to July 11, 2025. The funds were provided through a $180,000 convertible promissory note from Scilex Holding Company, with no interest, repayable upon business combination or liquidation. The note is convertible into Class A shares at $10 per share. Remaining funds may extend the deadline further.
2025-06-12 00:30
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
Scilex Holding Company announced the publication of GLOPERBA® dosing adjustments for patients with renal impairment in a peer-reviewed journal, providing optimized dosing to enhance safety and efficacy in gout flare prevention.
2025-06-05 16:05
STEALTHGAS INC. Announces the Date for the Release of the First Quarter 2025 Financial and Operating Results, Conference Call and Webcast
StealthGas Inc. will release its Q1 2025 financial results on May 28, 2025, followed by a conference call at 10:00 am ET. Participants can register via the provided link to access the call. A live and archived webcast will also be available on the company's website.
2025-05-22 13:59
Scilex Holding Company To Present "Prophylaxis Of Gout Flares In Patients With Renal Impairment: Dosing Adjustments With Colchicine Oral Solution Informed By A Pharmacokinetic Model" At The 2024 American College Of Rheumatology Convergence Conference In Washington, D.C. On November 14 – 19, 2024
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
2024-09-05 21:02
Scilex Unit Semnur Pharmaceuticals, Denali Capital Sign Merger Agreement
10:19 AM EDT, 09/03/2024 (MT Newswires) -- Scilex (SCLX) unit Semnur Pharmaceuticals and Denali Capital Acquisition (DECA) said Tuesday they have signed an agreement for a planned merger which provides for a pre-transaction equity value of Semnur at $2.5 billion. Upon closing of the deal, the combin...
2024-09-03 22:19
Scilex Holding Says US FDA Approves Supplemental New Drug Application for Precision Dosing of Gloperba Label
09:47 AM EDT, 08/29/2024 (MT Newswires) -- Scilex Holding (SCLX) said Thursday that the US Food and Drug Administration has approved the company's supplemental new drug application for precision dosing of the Gloperba label. Gloperba is an FDA-approved liquid formula of colchicine, an anti-gout medi...
2024-08-29 21:47
Scilex Says New US Patent to Be Issued for Pain Treatment
09:49 AM EDT, 08/21/2024 (MT Newswires) -- Scilex Holding (SCLX) said Wednesday that it is set to receive a new patent from the US Patent and Trademark Office later this year covering its claims related to acute pain treatment. The company said the US Patent and Trademark Office "has allowed numerou...
2024-08-21 21:49
